A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

Abstract

BackgroundPegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This observational study evaluated the efficacy and safety of PLD in patients treated during routine clinical practice.MethodsEligible patients had metastatic breast cancer and were treated with PLD according to the dose and schedule determined by their physician as part of routine practice. The primary objectives were to analyze the efficacy and toxicity of PLD therapy.Results125 patients were assessable. Median age was 62 years, 78% had performance status 0-1, and 60% had estrogen-receptor-positive disease. PLD treatment was second- or third-line in 69% of patients. Prior anthracyclines (adjuvant or metastatic) had been used in 56% of patients. The majority of patients (79%) received PLD every 4 weeks at a median dose of 40 mg/m2. Overall response rate was 43% in all patients and 34% in those previously treated with anthracyclines. The most common grade 3/4 adverse events were skin toxicity/hand-foot syndrome (6%), and leukopenia (3%).ConclusionsThis observational study supports the activity and tolerability of PLD in metastatic breast cancer as demonstrated in PLD clinical trials.

Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein

“…Liposomal carriers have proved to demonstrate beneficial pharmacokinetics/biodistribution of doxorubicin and, accordingly, reduced toxicity to normal organs (6, 35-37). Surface modification of liposomes with targeting ligands could further favor intratumoral distribution and intracellular delivery of drugs (7).…”

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

“…Geriatric assessment of these patients reveals that this is an unselected highly vulnerable population. Although the recommended dosage for PLD is 50 mg/m 2 every 28 days, we chose to administer an adjusted dose of 40 mg/m 2 , which matches routine practice 21 and has better tolerability and no compromised efficacy. 22 In a joint analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies on MBC treatment with 50 mg/m 2 PLD every 28 days, the authors reported a higher incidence of haematological toxicities (febrile neutropenia) in elderly patients (P70 years) compared to younger patients.…”

“…Median values for albumin and prealbumin were 39.0 g/L (29-51) and 0.22 g/L (0.08-0.35), respectively, and 16 (27%) patients had lymphocytes counts of 61 Â 10 3 /mm 3 . Median baseline ADL and IADL scores were 6 (2-6) and 24 (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27), respectively; 19 (32%) and 41 (68%) patients had at least one disability for ADL or an IADL score of 625, respectively. Seven (12%) patients lived in residential homes, and four (7%) lived in nursing homes.…”

Current Readings: Blood-Based Biomarkers for Lung Cancer

“…Chapman et al identified a panel of auto-antibodies that is now a part of a clinically available test for the early detection of lung cancer. In another auto-antibody study by Rom et al, autoantibody biomarkers were tested in a cohort of high risk smokers (n=158) with screening CT scans [17]. This cohort included lung cancer patients (n=22), smokers with sub-solid nodules (n=46), smokers with benign solid nodules (n=55), and smokers with normal CT scans (n=25).…”